Clinical Trial Finder

DISEASE CHARACTERISTICS:

• - Histologically proven glioblastoma multiforme.

• - Newly diagnosed disease.

• - Has undergone diagnostic biopsy or surgical resection within the past 28 days.

PATIENT CHARACTERISTICS:

• - ECOG 0-2.

• - Absolute neutrophil count ≥ 1,500/mm^3.

• - Platelet count ≥ 100,000/mm^3.

• - Hemoglobin > 9 g/L.

• - Serum creatinine and total serum bilirubin < 1.5 times upper limit of normal (ULN) - AST or ALT < 2.5 times ULN.

• - Alkaline phosphatase < 2.5 times ULN.

• - No other severe underlying disease (including HIV or chronic hepatitis B or C infection) - Fertile patients must use effective contraception.

• - Not pregnant or nursing.

• - No medical condition that could interfere with the oral administration of temozolomide or erlotinib hydrochloride.

• - No other malignancy within the past 3 years with the exception of surgically cured carcinoma in situ of the cervix, nonmelanoma skin cancer, or adequately treated stage I or II cancer from which the patient is in complete remission.

• - No active infection.

• - No other condition that would preclude ability of the patient to be followed closely at the Cleveland Clinic.

PRIOR CONCURRENT THERAPY:

• - No prior radiotherapy or chemotherapy for this cancer.

• - No prior cranial radiotherapy.

• - No concurrent enzyme-inducing anti-epileptic drugs.

• - No prior temozolomide or erlotinib hydrochloride.

• - No other concurrent antineoplastic therapy.

• - No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) during chemotherapy.

• - No concurrent electron, particle, or implant boost radiotherapy.

- No concurrent radiosurgery

OBJECTIVES:

• - Determine the progression-free survival and overall survival of patients with newly diagnosed glioblastoma multiforme treated with adjuvant radiotherapy, temozolomide, and erlotinib hydrochloride.

• - Evaluate the toxicity of this regimen in these patients.

OUTLINE: This is a non-randomized study. Patients receive oral temozolomide once daily on days 1-42 and undergo concurrent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Four weeks after completion of radiotherapy and temozolomide, patients receive oral temozolomide once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral erlotinib hydrochloride once daily beginning on day 1 of radiotherapy and continuing in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Arms

Experimental: Radiation Therapy, Temozolomide, and Erlotinib

Interventions

Drug: - erlotinib hydrochloride

Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.

Drug: - temozolomide

TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.

Radiation: - radiation therapy

Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.